RT Journal Article
T1 Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
A1 Barragan, Isabel
K1 DNA Methylation
K1 Epigenesis, Genetic
K1 Gene Expression Regulation, Neoplastic
AB The emergence of Immune Checkpoint Blockade (ICB) therapy has unleashed an abundance of promising cancer treatment alternatives that focus on the re-activation of an immunosuppressed tumour environment. These strategies, initially applied to advanced stages of cancer with durable responses and acceptable toxicity, are also transforming the clinical practice in the adjuvant and neoadjuvant settings and are indicated in more than 15 types of tumours. However, the frequent occurrence of innate or acquired resistance, of up to 85% of the patients, has turned the focus on precision medicine to decipher which patients will benefit from the treatment, and on combination therapies with multiple targets that can holistically combat the disease [1]. In this context, despite a nascent instrument in clinical practice, epigenetic marks stand as putative biomarkers informative both of response to immunotherapy and of the disease or therapy-induced dynamic landscape.
PB Elsevier
YR 2020
FD 2020-09-26
LK http://hdl.handle.net/10668/16337
UL http://hdl.handle.net/10668/16337
LA en
NO Barragan I. Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade. EBioMedicine. 2020 Oct;60:103005
NO The workin Isabel Barragan’s laboratory is funded by Instituto de Salud Carlos III through the project “PI18/01592” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”), Sistema Andaluz de Salud, Nicolas Monardes Program, through the project “SA 0263/ 2017”, Spanish Group of Melanoma (Award to Best Research Project 2020), Fundacion Bancaria Unicaja through the project “C19048”, and Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology.
DS RISalud
RD Apr 19, 2025